跳转至内容
Merck
CN

1.37069

10% 聚二烯丙基二甲基氯化铵溶液

EMPROVE® EVOLVE, Flocculation reagent

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

UNSPSC Code:
41116105
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


Quality Level

product line

EMPROVE® EVOLVE

form

liquid

pH

7.8 ( in H2O, ready-to-use solution)

density

1.015 g/cm3

storage temp.

15-25°C

Legal Information

Emprove is a registered trademark of Merck KGaA, Darmstadt, Germany


存储类别

12 - Non Combustible Liquids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable



使用 Emprove® 计划保持符合 GMP 要求

使用Emprove® Dossiers可加快资格认证、保持合规性并节省时间。

下载 Dossiers

注意:您将进入 EmproveSuite.com。您的用户名和密码与 SigmaAldrich.com 是分开的,可能不同

免费注册,几分钟内即可访问 Emprove® Dossiers 升级您的订阅计划,解锁 Emprove® Suite 中的高级定制内容。

没有找到您要找的内容?访问 Emprove® 计划帮助页面

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库


商品

Influenza vaccines are commonly made using egg-based and cell-based manufacturing strategies. Find step-by-step information on the manufacturing process for each method.

A custom-designed cost model is used to explore the economics of vaccine manufacturing across several different modalities including mRNA. The model enables greater process understanding, simulates bottlenecks, and helps to optimize production efficiency.

Learn more one the attenuated viral vaccines manufacturing process: cell culture, clarification, nuclease treatment, chromatography, and sterile filtration.

查看所有文章

相关内容

Learn more on mAb downstream processing, more specifically clarification and the relevant associated products.

Flocculants, like pDADMAC, remove cell debris during downstream monoclonal antibody production, but their adoption has been difficult due to perceived regulatory concerns.

This technical article breaks down the adenovirus vaccine manufacturing process and provides a case study on developing an accelerated and cost-effective single-use adenoviral vector vaccine.

查看所有相关内容